By the end of January, the Beijing Institute of Biological Products Co. Ltd. (BIBP), a subsidiary of Chinese pharmaceutical giant Sinopharm, had produced almost 2.3 billion COVID-19 vaccine doses, ranking it the second-largest manufacturer of COVID-19 vaccines in the country. Although most Sinopharm BIBP vaccines are used domestically within China, a large number of doses were also exported worldwide through sales and donations. The company also constructed production sites with local partners in a number of countries to enable vaccine productions locally.
Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022
(in millions)
Beijing Institute of Biological Products Co. Ltd. (BIBP) is a subsidiary of Sinopharm, producing one of the two types of Sinopharm's COVID-19 vaccines.
Data for months prior to December 2021 come from previous reports.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Global Commission for Post-Pandemic Policy. (February 10, 2022). Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions) [Graph]. In Statista. Retrieved November 21, 2024, from https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
Global Commission for Post-Pandemic Policy. "Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions)." Chart. February 10, 2022. Statista. Accessed November 21, 2024. https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
Global Commission for Post-Pandemic Policy. (2022). Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions). Statista. Statista Inc.. Accessed: November 21, 2024. https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
Global Commission for Post-Pandemic Policy. "Cumulative Number of Covid-19 Vaccine Doses Manufactured by Sinopharm Bibp between April 2021 and January 2022 (in Millions)." Statista, Statista Inc., 10 Feb 2022, https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
Global Commission for Post-Pandemic Policy, Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions) Statista, https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/ (last visited November 21, 2024)
Cumulative number of COVID-19 vaccine doses manufactured by Sinopharm BIBP between April 2021 and January 2022 (in millions) [Graph], Global Commission for Post-Pandemic Policy, February 10, 2022. [Online]. Available: https://www.statista.com/statistics/1306831/sinopharm-covid19-vaccine-production-figures/
